S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
+0.00
+0.00%
URGN · UroGen Pharma Ltd. Ordinary Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Urogen Pharma Ltd (URGN)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$35.47
+0.48
(+1.39%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$35.47
$35.20
$36.35
52-WEEK RANGE
$35.47
$16.36
$50.81
What's happening
- URGN is up 1.39% today, trading at $35.47. — Live quote
- Volume today (42,228) is well below its 3-month average of 860,600. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.28 actual vs. $-0.29 estimated (+4.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
URGN
+49.49%
vs S&P 500
+36.71%
1-YEAR RETURN
URGN
+94.55%
vs S&P 500
+79.99%
6-MONTH RETURN
URGN
+63.67%
3-MONTH RETURN
URGN
-20.03%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.28
Est. $-0.29
BEAT +4.4%
2026-04-26 (Q1 2026)
$-0.47
Est. $-0.49
BEAT +4.5%
2026-01-26 (Q4 2025)
$-0.54
Est. $-0.51
MISS -5.4%
2025-10-26 (Q3 2025)
$-0.69
Est. $-0.71
BEAT +2.3%
Valuation Measures & Ratios
Enterprise Value4$1.87B
Forward P/E521.78
PEG Ratio6—
Price / Sales (TTM1)9.28
Price / Book720.96
EV4 / Revenue9.88
EV4 / EBITDA—
Profit Margin-51.73%
Operating Margin-35.32%
Return on Equity (ROE8)-204.47%
Return on Assets (ROA9)-43.79%
Avg Volume (3M)860,600
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short7,766,918
Change from Prior Settlement+24.32%
% of Float—
Days to Cover (Short Ratio)9.91
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 199.2% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +94.6%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -51.7%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-09; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on URGN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.5M | $51.0M | $27.5M | $24.2M | $20.3M | $24.6M | $25.2M | $21.8M |
| Gross profit | $65.9M | $46.8M | $24.2M | $20.7M | $17.9M | $22.1M | $22.8M | $19.6M |
| Operating income | $111.0K | -$20.3M | -$27.4M | -$41.4M | -$36.9M | — | -$17.5M | -$25.8M |
| Net income | -$14.4M | -$23.6M | -$33.3M | -$49.9M | -$43.8M | -$37.5M | -$23.7M | -$33.4M |
| EPS (basic) | $-0.28 | $-0.47 | $-0.69 | $-1.05 | $-0.92 | $-0.80 | $-0.51 | $-0.82 |
| Operating margin | $0 | -$40 | -$100 | -$171 | -$182 | — | -$70 | -$118 |
| Net margin | -$20 | -$46 | -$121 | -$206 | -$216 | -$153 | -$94 | -$153 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $252.6M | $253.7M | $200.5M | $185.0M | $208.7M | $247.6M | $285.7M | $301.9M |
| Total liabilities | $385.0M | $377.9M | $305.9M | $300.5M | $302.1M | $294.1M | $294.5M | $276.4M |
| Stockholders' equity | -$132.4M | -$124.3M | -$105.5M | -$115.4M | -$93.4M | -$46.5M | -$8.8M | $25.5M |
| Total current assets | $235.4M | $237.5M | $186.0M | $168.5M | $196.9M | $237.2M | $276.1M | $295.1M |
| Total current liabilities | $61.9M | $50.6M | $46.4M | $42.2M | $47.5M | $42.0M | $45.9M | $32.8M |
| Cash & equivalents | $79.1M | $110.0M | $110.7M | $90.0M | $92.9M | $104.0M | $172.0M | $124.9M |
| Marketable securities (current) | $30.2M | $39.7M | $49.3M | $63.8M | $83.1M | $112.0M | $110.7M | $153.9M |
| Accounts receivable | $88.8M | $55.4M | $33.1M | $19.7M | $19.6M | $19.6M | $20.3M | $22.8M |
| Inventory | $24.6M | $20.9M | $16.5M | $8.3M | $7.1M | $7.6M | $9.2M | $7.6M |
| Property, plant & equipment | $597.0K | $616.0K | $637.0K | $695.0K | $688.0K | $627.0K | $655.0K | $608.0K |
| Other non-current assets | $8.8M | $7.5M | $5.2M | $6.8M | $801.0K | $371.0K | $589.0K | $370.0K |
| Accounts payable | $15.5M | $17.2M | $12.1M | $10.3M | $13.6M | $14.6M | $10.9M | $5.6M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | $7.6M | $5.5M | $3.4M | $5.0M | $4.9M | $4.7M | $7.9M | $4.1M |
| Long-term debt | $188.7M | $189.5M | $122.2M | $122.1M | $122.5M | $122.1M | $121.7M | $121.7M |
| Common stock & paid-in capital | $135.0K | $134.0K | $133.0K | $128.0K | $126.0K | $126.0K | $115.0K | $115.0K |
| Retained earnings | -$997.6M | -$983.3M | -$959.7M | -$933.4M | -$900.0M | -$850.1M | -$806.2M | -$768.7M |
| Accumulated other comprehensive income (loss) | -$2.0K | $8.0K | $19.0K | $23.0K | $6.0K | $14.0K | $56.0K | $236.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.0M | -$45.3M | -$38.3M | -$42.3M | -$39.8M | -$42.0M | -$13.6M | -$27.7M |
| Investing cash flow | $1.7M | -$20.7M | $27.7M | $31.4M | $28.4M | -$26.0M | $60.6M | -$106.8M |
| Financing cash flow | $500.0K | $65.2M | $31.3M | $8.3M | $296.0K | $34.0K | $71.0K | $39.6M |
| Free cash flow | -$33.1M | -$45.4M | -$38.3M | -$42.4M | -$40.0M | -$42.1M | -$13.7M | -$27.8M |
| Capital expenditures | $60.0K | $54.0K | $17.0K | $87.0K | $141.0K | $44.0K | $115.0K | $96.0K |
| Depreciation & amortization | $100.0K | $75.0K | $235.0K | $100.0K | $100.0K | $72.0K | $206.0K | $100.0K |
| Share-based compensation | $5.3M | $4.6M | $3.1M | $3.0M | $2.7M | $3.1M | $3.3M | $3.5M |
| Change in accounts receivable | $33.3M | $22.3M | $13.4M | $54.0K | $11.0K | -$664.0K | -$2.5M | $5.4M |
| Change in inventory | $3.7M | $4.5M | $8.1M | $1.2M | -$462.0K | -$1.6M | $1.6M | $152.0K |
| Purchases of investments | $0 | $24.8M | $539.0K | $8.7M | $1.8M | $66.4M | $9.2M | $118.8M |
| Sales/maturities of investments | $1.7M | $4.1M | $28.3M | $40.2M | $30.3M | $40.4M | $70.0M | $12.1M |
| Debt issued | $0 | $65.3M | $0 | $0 | $0 | $0 | $0 | $24.5M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M | $42.9M |
| Operating income | -$124.9M | -$96.8M | -$65.5M | -$79.0M | -$92.3M |
| Net income | -$153.5M | -$126.9M | -$102.2M | -$109.8M | -$110.8M |
| EPS (basic) | $-3.19 | $-2.96 | $-3.55 | $-4.81 | $-4.96 |
| Operating margin | -$114 | -$107 | -$79 | -$123 | -$192 |
| Net margin | -$140 | -$140 | -$124 | -$171 | -$231 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $200.5M | $285.7M | $178.3M | $135.6M | $119.7M |
| Total liabilities | $305.9M | $294.5M | $243.5M | $225.0M | $111.3M |
| Stockholders' equity | -$105.5M | -$8.8M | -$65.2M | -$89.4M | $8.4M |
| Total current assets | $186.0M | $276.1M | $169.2M | $128.9M | $114.4M |
| Total current liabilities | $46.4M | $45.9M | $31.2M | $23.9M | $22.4M |
| Cash & equivalents | $110.7M | $172.0M | $95.0M | $55.4M | $44.4M |
| Marketable securities (current) | $49.3M | $110.7M | $56.2M | — | — |
| Accounts receivable | $33.1M | $20.3M | $15.4M | $12.7M | $11.7M |
| Inventory | $16.5M | $9.2M | $5.7M | $4.3M | $4.8M |
| Property, plant & equipment | $637.0K | $655.0K | $689.0K | $1.3M | $2.0M |
| Other non-current assets | $5.2M | $589.0K | $2.0M | $2.7M | $1.3M |
| Accounts payable | $12.1M | $10.9M | $6.5M | $5.5M | $5.8M |
| Deferred revenue (current) | — | — | — | — | — |
| Other current liabilities | $5.2M | $7.9M | $3.9M | $3.3M | $3.3M |
| Long-term debt | $122.2M | $121.7M | $98.6M | $97.5M | $0 |
| Common stock & paid-in capital | $133.0K | $115.0K | $89.0K | $63.0K | $61.0K |
| Retained earnings | -$959.7M | -$806.2M | -$679.3M | -$577.1M | -$467.3M |
| Accumulated other comprehensive income (loss) | $19.0K | $56.0K | $12.0K | -$107.0K | -$25.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$162.4M | -$96.8M | -$76.4M | -$87.6M | -$84.9M |
| Investing cash flow | $61.6M | -$20.6M | -$953.0K | $1.1M | $4.1M |
| Financing cash flow | $39.9M | $194.6M | $116.9M | $97.1M | $72.3M |
| Free cash flow | -$162.7M | -$97.1M | -$76.6M | -$87.8M | -$85.6M |
| Capital expenditures | $289.0K | $295.0K | $194.0K | $254.0K | $752.0K |
| Depreciation & amortization | $307.0K | $329.0K | $802.0K | $924.0K | $831.0K |
| Share-based compensation | $12.0M | $13.1M | $9.3M | $10.6M | $23.1M |
| Change in accounts receivable | $12.8M | $4.9M | $2.7M | $987.0K | $4.7M |
| Change in inventory | $7.2M | $3.6M | $1.3M | $362.0K | $2.9M |
| Purchases of investments | $77.4M | $128.0M | $49.8M | $63.0M | $51.9M |
| Sales/maturities of investments | $139.2M | $107.7M | $49.1M | $64.3M | $54.3M |
| Debt issued | $0 | $24.5M | $0 | $95.8M | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding URGN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers74.5%
Shares Outstanding50,380,112
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 4,543,895 | $167.2M | 9.02% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 3,201,461 | $117.8M | 6.35% | +12.5% | 2026-08-07 |
| Morgan Stanley | 2,576,363 | $94.8M | 5.11% | +0.6% | 2026-08-11 |
| Kynam Capital Management, LP | 2,434,207 | $89.6M | 4.83% | +8.3% | 2026-08-14 |
| Jefferies Financial Group Inc. | 2,199,652 | $80.9M | 4.37% | +0.0% | 2026-08-14 |
| SG Americas Securities, LLC | 2,052,906 | $75.5K | 4.07% | +23.8% | 2026-08-07 |
| AMERICAN CENTURY COMPANIES INC | 1,685,719 | $62.0M | 3.35% | +2.9% | 2026-08-12 |
| ACORN CAPITAL ADVISORS, LLC | 1,673,420 | $61.6M | 3.32% | +0.0% | 2026-08-14 |
| Point72 Asset Management, L.P. | 1,525,549 | $56.1M | 3.03% | +0.0% | 2026-08-14 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1,508,547 | $55.5M | 2.99% | +14.8% | 2026-08-14 |
| Opaleye Management Inc. | 1,439,996 | $53.0M | 2.86% | +0.7% | 2026-08-14 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,301,979 | $47.9M | 2.58% | -13.4% | 2026-08-07 |
| MENORA MIVTACHIM HOLDINGS LTD. | 1,152,531 | $42.4M | 2.29% | +0.0% | 2026-08-13 |
| D. E. Shaw & Co., Inc. | 1,145,819 | $42.2M | 2.27% | +12.0% | 2026-08-14 |
| State Street Corp | 1,003,071 | $36.9M | 1.99% | +14.7% | 2026-08-07 |
| MPM BioImpact LLC | 933,415 | $34.3M | 1.85% | -1.1% | 2026-08-14 |
| Soleus Capital Management, L.P. | 829,810 | $30.5M | 1.65% | +14.1% | 2026-08-11 |
| Goldman Sachs Group Inc | 819,834 | $30.2M | 1.63% | +37.0% | 2026-08-14 |
| Migdal Insurance & Financial Holdings Ltd. | 770,909 | $28.4M | 1.53% | +0.0% | 2026-08-10 |
| ORBIMED ADVISORS LLC | 676,187 | $24.9M | 1.34% | -22.8% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 610,364 | $22.5M | 1.21% | +16.5% | 2026-08-12 |
| Woodline Partners LP | 500,726 | $18.4M | 0.99% | +0.0% | 2026-08-14 |
| Boxer Capital Management, LLC | 500,000 | $18.4M | 0.99% | +0.0% | 2026-08-14 |
| Bank Of America Corp /De/ | 475,702 | $17.5M | 0.94% | +275.2% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 456,558 | $16.8M | 0.91% | +11.5% | 2026-06-30 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-02-26 to 2026-10-08
Recent transactions
- Insiders have net sold 100,491 shares over the last 182 days, across 0 purchases and 8 sales.
- Most recent: Degnan Chris (Chief Financial Officer) — Option exercise of 4,483 shares on 2026-10-08.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)100,491 sh(8 txns)
Net Shares-100,491
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Degnan Chris | Chief Financial Officer | Option exercise | 2026-10-08 | 4,483 |
| Schoenberg Mark | Chief Medical Officer | Open market sale | 2026-09-08 | 871 |
| Smith Jason Drew | General Counsel | Open market sale | 2026-09-08 | 1,519 |
| Robinson James A. Jr. | Director | Option exercise | 2026-08-26 | 2,000 |
| Holden Stuart | Director | Option exercise | 2025-11-26 | 2,000 |
| BUTITTA CYNTHIA M | Director | Option exercise | 2025-11-26 | 2,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-08 | Degnan Chris | Chief Financial Officer | Option exercise | 4,483 | — |
| 2026-10-08 | Degnan Chris | Chief Financial Officer | Open market sale | 2,202 | $36.69 |
| 2026-09-08 | Schoenberg Mark | Chief Medical Officer | Open market sale | 871 | $42.92 |
| 2026-09-08 | Smith Jason Drew | General Counsel | Open market sale | 1,519 | $42.54 |
| 2026-09-07 | Schoenberg Mark | Chief Medical Officer | Option exercise | 1,667 | — |
| 2026-09-07 | Smith Jason Drew | General Counsel | Option exercise | 3,334 | — |
| 2026-08-26 | Robinson James A. Jr. | Director | Option exercise | 2,000 | — |
| 2026-08-20 | Schoenberg Mark | Chief Medical Officer | Open market sale | 60,677 | $47.05 |
| 2026-07-09 | Schoenberg Mark | Chief Medical Officer | Open market sale | 10,000 | $40.00 |
| 2026-06-22 | Schoenberg Mark | Chief Medical Officer | Open market sale | 10,000 | $35.01 |
| 2026-06-08 | Schoenberg Mark | Chief Medical Officer | Option exercise | 10,000 | — |
| 2026-06-08 | Schoenberg Mark | Chief Medical Officer | Open market sale | 5,222 | $27.30 |
| 2026-05-26 | Robinson James A. Jr. | Director | Option exercise | 2,000 | — |
| 2026-05-08 | Schoenberg Mark | Chief Medical Officer | Open market sale | 10,000 | $30.00 |
| 2026-02-03 | Smith Jason Drew | General Counsel | Open market sale | 2,654 | $19.69 |
| 2026-02-03 | Smith Jason Drew | General Counsel | Open market sale | 1,608 | $19.69 |
| 2026-02-03 | Smith Jason Drew | General Counsel | Open market sale | 3,217 | $19.69 |
| 2026-02-03 | Schoenberg Mark | Chief Medical Officer | Open market sale | 1,844 | $19.69 |
| 2026-02-03 | Schoenberg Mark | Chief Medical Officer | Open market sale | 1,843 | $19.69 |
| 2026-02-03 | Schoenberg Mark | Chief Medical Officer | Open market sale | 3,686 | $19.69 |
| 2026-01-31 | Smith Jason Drew | General Counsel | Option exercise | 5,500 | — |
| 2026-01-31 | Smith Jason Drew | General Counsel | Option exercise | 3,333 | — |
| 2026-01-31 | Smith Jason Drew | General Counsel | Option exercise | 6,667 | — |
| 2026-01-31 | Schoenberg Mark | Chief Medical Officer | Option exercise | 3,333 | — |
| 2026-01-31 | Schoenberg Mark | Chief Medical Officer | Option exercise | 6,666 | — |
| 2026-01-31 | Schoenberg Mark | Chief Medical Officer | Option exercise | 3,334 | — |
| 2025-11-26 | Holden Stuart | Director | Option exercise | 2,000 | — |
| 2025-11-26 | BUTITTA CYNTHIA M | Director | Option exercise | 2,000 | — |
| 2025-11-26 | Robinson James A. Jr. | Director | Option exercise | 2,000 | — |
| 2025-02-26 | Robinson James A. Jr. | Director | Option exercise | 2,000 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:09 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-09 | 4 | 2026-10-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-07 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-07 | View on SEC.gov → |
| 2026-08-28 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-20 | 8-K | 2026-08-18 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-10 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-22 | View on SEC.gov → |
Recent news
Headlines about URGN (UroGen Pharma Ltd. Ordinary Shares). Links open the publisher — we don’t host full articles.
-
Why UroGen Pharma (URGN) Is Getting Fresh Attention Now
Yahoo · 2026-10-20 -
UroGen Pharma (URGN) Wins FDA Filing Acceptance, Is The Stock Still Cheap?
Simply Wall Street · 2026-10-20 -
URGN Jan 2027 45.000 put (URGN270115P00045000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-20 -
URGN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $75
GuruFocus · 2026-10-19 -
UroGen Pharma (URGN) FDA Accepts Marketing Application for UGN-1
GuruFocus · 2026-10-19 -
UroGen gets FDA review for new bladder cancer therapy
Seeking Alpha · 2026-10-19 -
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
Yahoo · 2026-10-19 -
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target
Benzinga · 2026-10-19
No headlines in this category right now — try “All”.